Patterns of practice and pharmacoeconomic analysis of the management of patients with metastatic renal cell carcinoma (mRCC) in Greece––the CRISIS study. A retrospective analysis by the Hellenic Genitourinary Cancer Group (HGUCG)

References

• Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975–2014, National Cancer Institute April 2017; based on November 2016 SEER data submission]. [cited 2018 Jul]. Available from: https://seer.cancer.gov/csr/1975_2014/
   Google Scholar
• Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008 v1.2, cancer incidence and mortality worldwide: IARC cancerbase no. 10 [intern.lyon, France: International Agency for Research on Cancer 2010 [cited2013 Jun]. Available from: http://globocan.iarc.fr/
   Google Scholar
• Ljungberg B, Albiges L, Bensalah K, et al. Guidelines on renal cell carcinoma. European Association of Urology [ cited 2018 Jul]. Available from: http://uroweb.org/guideline/renal-cell-carcinoma/#1
   Google Scholar
• Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002 Jan 1;20(1):289–296. PubMed PMID: 11773181.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007 Jan 11;356(2):115–124. PubMed PMID: 17215529.
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010 Feb 20;28(6):1061–1068. PubMed PMID: 20100962.
   PubMed Web of Science ®Google Scholar
• Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007 Dec 22;370(9605):2103–2111. PubMed PMID: 18156031.
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007 May 31;356(22):2271–2281. PubMed PMID: 17538086.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial. J Clin Oncol. 2017 Feb 20;35(6):591–597. PubMed PMID: 28199818.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013 Aug 22;369(8):722–731. PubMed PMID: 23964934.
   PubMed Web of Science ®Google Scholar
• Escudier B, Porta C, Bono P, et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study. J Clin Oncol. 2014 May 10;32(14):1412–1418. PubMed PMID: 24687826.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008 Aug 9;372(9637):449–456. PubMed PMID: 18653228.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016 Jul;17(7):917–927. . PubMed PMID: 27279544.
   PubMed Web of Science ®Google Scholar
• Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011 Dec 3;378(9807):1931–1939. PubMed PMID: 22056247.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015 Nov 5;373(19):1803–1813. PubMed PMID: 26406148; PubMed Central PMCID: PMC5719487.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015 Nov;16(15):1473–1482. PubMed PMID: 26482279.
   PubMed Web of Science ®Google Scholar
• Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016 Sep;27(suppl 5):v58–v68. PubMed PMID: 27664262.
   PubMed Web of Science ®Google Scholar
• Heng DY, Choueiri TK, Rini BI, et al. Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Ann Oncol. 2014 Jan;25(1):149–154. PubMed PMID: 24356626; PubMed Central PMCID: PMC4155479.
   PubMed Web of Science ®Google Scholar
• Bamias A, Manios E, Karadimou A, et al. The use of 24-h ambulatory blood pressure monitoring (ABPM) during the first cycle of sunitinib improves the diagnostic accuracy and management of hypertension in patients with advanced renal cancer. Eur J Cancer. 2011 Jul;47(11):1660–1668. PubMed PMID: 21549588.
   PubMed Web of Science ®Google Scholar
• Eisen T, Sternberg CN, Robert C, et al. Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst. 2012 Jan 18;104(2):93–113. PubMed PMID: 22235142.
   PubMed Web of Science ®Google Scholar
• De Groot S, Blommestein HM, Redekop WK, et al. Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: a real-world cost-effectiveness analysis of sequential first- and second-line treatments. PloS one. 2017;12(5):e0177364. . PubMed PMID: 28531203; PubMed Central PMCID: PMC5439671
   PubMed Web of Science ®Google Scholar
• Bamias A, Karadimou A, Lampaki S, et al. Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the memorial sloan-kettering prognostic factors model. BMC Cancer. 2010 Feb;18(10):45. . PubMed PMID: 20163744; PubMed Central PMCID: PMC2837011.
   PubMed Web of Science ®Google Scholar
• Soerensen AV, Donskov F, Hermann GG, et al. Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: results from the Danish renal cancer group (DARENCA) study-2. Eur J Cancer. 2014 Feb;50(3):553–562. PubMed PMID: 24215846.
   PubMed Web of Science ®Google Scholar
• Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 2009 Aug;10(8):757–763. PubMed PMID: 19615940.
   PubMed Web of Science ®Google Scholar
• Bamias A, Escudier B, Sternberg CN, et al. Current clinical practice guidelines for the treatment of renal cell carcinoma: a systematic review and critical evaluation. Oncologist. 2017 Jun;22(6):667–679. PubMed PMID: 28592625; PubMed Central PMCID: PMC5469586.
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Calabro F, Bracarda S, et al. Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial. Oncology. 2015;88(5):273–280. . PubMed PMID: 25592399
   PubMed Web of Science ®Google Scholar
• Perez-Valderrama B, Arranz Arija JA, Rodriguez Sanchez A, et al. Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study. Ann Oncol. 2016 Apr;27(4):706–711. PubMed PMID: 26658889.
   PubMed Web of Science ®Google Scholar
• Pal SK, Ghate SR, Li N, et al. Real-world survival outcomes and prognostic factors among patients receiving first targeted therapy for advanced renal cell carcinoma: a SEER-medicare database analysis. Clin Genitourin Cancer. 2017 Aug;15(4):e573–e582. PubMed PMID: 28139444.
   PubMed Web of Science ®Google Scholar
• Tanaka N, Mizuno R, Ito K, et al. External validation of the MSKCC and IMDC risk models in patients treated with targeted therapy as a first-line and subsequent second-line treatment: a Japanese multi-institutional study. Eur Urol Focus. 2016 Aug;2(3):303–309. PubMed PMID: 28723377.
   PubMedGoogle Scholar
• Poprach A, Fiala O, Chloupkova R, et al. Pazopanib for metastatic renal cell Carcinoma: a registry-based analysis of 426 patients. Anticancer Res. 2018 Jan;38(1):449–456. PubMed PMID: 29277808.
   PubMed Web of Science ®Google Scholar
• Kentikelenis A, Karanikolos M, Reeves A, et al. Greece’s health crisis: from austerity to denialism. Lancet. 2014 Feb 22;383(9918):748–753. PubMed PMID: 24560058.
   PubMed Web of Science ®Google Scholar
• Sanidas EA, Papaioannou TG, Papadopoulos DP, et al. The impact of financial crisis in coronary artery disease burden in Greece. Hellenic J Cardiol = Hellenike Kardiologike Epitheorese. 2018 Mar 27. DOI:10.1016/j.hjc.2018.03.003. [ PubMed PMID: 29601956].
   Google Scholar
• Kotsiou OS, Zouridis S, Kosmopoulos M, et al. Impact of the financial crisis on COPD burden: Greece as a case study. Eur Respir Rev. 2018 Mar 31;27(147). PubMed PMID: 29367410. DOI:10.1183/16000617.0106-2017.
   PubMed Web of Science ®Google Scholar
• Bamias A, Peroukidis S, Stamatopoulou S, et al. Utilization of systemic chemotherapy in advanced urothelial cancer: a retrospective collaborative study by the Hellenic Genitourinary Cancer Group (HGUCG). Clin Genitourin Cancer. 2016 Apr;14(2):e153–9. PubMed PMID: 26437909.
   PubMed Web of Science ®Google Scholar
• Papaxoinis G, Kotoula V, Giannoulatou E, et al. Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping. Med Oncol. 2018 May 31;35(7):101. PubMed PMID: 29855806.
   PubMed Web of Science ®Google Scholar
• Katopodis O, Souglakos J, Stathopoulos E, et al. Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). Cancer Chemother Pharmacol. 2014 Aug;74(2):333–340. PubMed PMID: 24930058.
   PubMed Web of Science ®Google Scholar
• Capri S, Porta C, Delea TE. Cost-effectiveness of pazopanib versus sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma from an Italian National Health Service Perspective. Clin Ther. 2017 Mar;39(3):567–580 e2. . PubMed PMID: 28189363
   PubMed Web of Science ®Google Scholar
• Maroun R, Fleury L, Nachbaur G, et al. Real-world costs and outcomes in metastatic renal cell carcinoma patients treated with targeted therapies: a cohort study from the French health insurance database. Curr Med Res Opin. 2017 Oct;33(10):1755–1762. PubMed PMID: 28748721.
   PubMed Web of Science ®Google Scholar
• Vogler S, Vitry A, Babar ZU. Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study. Lancet Oncol. 2016 Jan;17(1):39–47. . PubMed PMID: 26670089
   PubMed Web of Science ®Google Scholar
• Panteli D, Arickx F, Cleemput I, et al. Pharmaceutical regulation in 15 European countries review. Health Syst Transit. 2016 Oct;18(5):1–122. PubMed PMID: 27929376
   Google Scholar